JP2010508349A - ジプテリニルカルシウム五水和物（ｄｃｐ）およびそれに基づく治療法 - Google Patents

ジプテリニルカルシウム五水和物（ｄｃｐ）およびそれに基づく治療法 Download PDF

Info

Publication number
JP2010508349A
JP2010508349A JP2009535306A JP2009535306A JP2010508349A JP 2010508349 A JP2010508349 A JP 2010508349A JP 2009535306 A JP2009535306 A JP 2009535306A JP 2009535306 A JP2009535306 A JP 2009535306A JP 2010508349 A JP2010508349 A JP 2010508349A
Authority
JP
Japan
Prior art keywords
dcp
administering
effective amount
subject
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009535306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010508349A5 (enExample
Inventor
モヘノ，フィリップ
フレイデラー，ウォルフガング
Original Assignee
サンアールエックス ファーマスーティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サンアールエックス ファーマスーティカルズ，インク． filed Critical サンアールエックス ファーマスーティカルズ，インク．
Publication of JP2010508349A publication Critical patent/JP2010508349A/ja
Publication of JP2010508349A5 publication Critical patent/JP2010508349A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
JP2009535306A 2006-10-30 2007-10-30 ジプテリニルカルシウム五水和物（ｄｃｐ）およびそれに基づく治療法 Pending JP2010508349A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86354706P 2006-10-30 2006-10-30
PCT/US2007/023012 WO2008054793A2 (en) 2006-10-30 2007-10-30 Dipterinyl calcium pentahydrate (dcp) and therapeutic methods based thereon

Publications (2)

Publication Number Publication Date
JP2010508349A true JP2010508349A (ja) 2010-03-18
JP2010508349A5 JP2010508349A5 (enExample) 2010-11-11

Family

ID=39344907

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009535306A Pending JP2010508349A (ja) 2006-10-30 2007-10-30 ジプテリニルカルシウム五水和物（ｄｃｐ）およびそれに基づく治療法

Country Status (7)

Country Link
US (2) US7662820B2 (enExample)
EP (1) EP2094715B1 (enExample)
JP (1) JP2010508349A (enExample)
CN (1) CN101663308A (enExample)
CA (1) CA2668262A1 (enExample)
ES (1) ES2394227T3 (enExample)
WO (1) WO2008054793A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003257589A1 (en) * 2002-08-22 2004-03-11 Sumitomo Pharmaceuticals Company, Limited Remedy for integration dysfunction syndrome
AU2004249621B2 (en) 2003-06-23 2009-08-06 Dainippon Sumitomo Pharma Co., Ltd. Therapeutic agent for senile dementia
WO2005080976A1 (ja) * 2004-02-20 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. 統合失調症の記憶・学習機能障害治療薬のin vivoスクリーニング方法
EP2502628B1 (en) 2006-06-23 2016-12-14 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
CN101663308A (zh) * 2006-10-30 2010-03-03 桑尔克斯药品公司 N-甲基色胺钙五水合物(dcp)和基于它的治疗方法
US20120251495A1 (en) * 2008-01-18 2012-10-04 Phillip Moheno Pterin based therapies for inflammatory conditions
WO2010060186A1 (en) 2008-11-03 2010-06-03 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
DK3173427T3 (da) 2011-03-31 2019-08-05 Adc Therapeutics Sa Antistoffer mod nyre-associeret antigen 1 og antigen-bindende fragmenter deraf
HRP20190946T1 (hr) 2012-01-09 2019-07-26 Adc Therapeutics Sa Sredstva za liječenje trostruko negativnog raka dojke
WO2013116238A1 (en) * 2012-01-30 2013-08-08 Sanrx Pharmaceuticals, Inc. Calcium folate (cafolate) and therapeutic methods based thereon
CN104788300B (zh) * 2014-01-22 2017-01-11 南京华威医药科技开发有限公司 欧司哌米芬多晶型

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002527518A (ja) * 1998-10-22 2002-08-27 フィリップ・ビー・ビー・モヘノ 新規なプテリン抗新生物薬

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2342797A1 (en) 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
DE19944767A1 (de) * 1999-09-17 2001-03-29 Vasopharm Biotech Gmbh & Co Kg N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101663308A (zh) * 2006-10-30 2010-03-03 桑尔克斯药品公司 N-甲基色胺钙五水合物(dcp)和基于它的治疗方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002527518A (ja) * 1998-10-22 2002-08-27 フィリップ・ビー・ビー・モヘノ 新規なプテリン抗新生物薬

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6013003429; Ｍｏｌ．　Ｃｒｙｓｔ．　Ｌｉｑ．　Ｃｒｙｓｔ． Ｖｏｌ．２７６, 1996, Ｐ．２２９-２３５ *
JPN6013003430; Ｉｎｏｒｇ．　Ｃｈｅｍ． Ｖｏｌ．３４, 1995, Ｐ．３３６７-３３７０ *

Also Published As

Publication number Publication date
US7662820B2 (en) 2010-02-16
US20080166355A1 (en) 2008-07-10
CA2668262A1 (en) 2008-05-08
WO2008054793A3 (en) 2008-08-28
EP2094715A2 (en) 2009-09-02
US20100105692A1 (en) 2010-04-29
ES2394227T3 (es) 2013-01-23
WO2008054793A2 (en) 2008-05-08
EP2094715A4 (en) 2010-04-28
EP2094715B1 (en) 2012-08-29
CN101663308A (zh) 2010-03-03

Similar Documents

Publication Publication Date Title
JP2010508349A (ja) ジプテリニルカルシウム五水和物（ｄｃｐ）およびそれに基づく治療法
CA3091444A1 (en) Microbiome related immunotherapies
US20210147472A1 (en) Solid forms and formulations comprising a glucocorticoid receptor antagonist and uses thereof
TW201513864A (zh) 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑
MD3661373T2 (ro) Compoziție farmaceutică pentru tratamentul anemiei
WO2016001907A1 (en) Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
JPWO2010110223A1 (ja) 抗腫瘍作用を有するフコイダン
JPWO2005094878A1 (ja) 抗腫瘍作用を有する組成物
TW201728328A (zh) 針對具有重度腎功能障礙之癌症患者之治療方法
EP2097085A2 (en) Therapeutic materials and methods
CN117298043A (zh) 一种纳米水凝胶前驱体及其制备方法与应用
CN105078944A (zh) Isopaucifloral F在制备抗骨质疏松药物中的用途
CN104434948B (zh) 一种抗胰腺癌的药物组合物及其应用
CN116271090A (zh) 一种具有tlr9激动剂活性的dna纳米笼及其在制备抗肿瘤药物中的应用
CN102451183B (zh) 一种孕甾双烯醇酮类化合物在制备抗肿瘤药物中的应用
US20170087125A1 (en) Flavonoid compositions for the treatment of cancer
HK1139952A (en) Dipterinyl calcium pentahydrate (dcp) and therapeutic methods based thereon
CN102245021A (zh) 安莎霉素氢醌组合物
CN106854223A (zh) 氮芥槲皮素衍生物及其制备方法和用途
RU2015152096A (ru) Средство (варианты) и способы восстановления микрофлоры
JPWO2015152407A1 (ja) 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤
US20220305026A1 (en) Use of polaprezinc in preparing drug for treating castration-resistant prostate cancer
EP4226939A1 (en) Novel use of mycobacterium tuberculosis extract
CN106236766A (zh) 一种包含稀有人参皂苷Rk3的稀有人参皂苷组合物
JP4512322B2 (ja) 癌転移抑制剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130702